Recombinant human defensin for management of ileal Crohn's disease

Award Information
Agency:
Department of Health and Human Services
Amount:
$189,300.00
Program:
SBIR
Contract:
1R43AI069577-01
Solitcitation Year:
2006
Solicitation Number:
PHS2006-2
Branch:
N/A
Award Year:
2006
Phase:
Phase I
Agency Tracking Number:
AI069577
Solicitation Topic Code:
N/A
Small Business Information
VENTRIA BIOSCIENCE
VENTRIA BIOSCIENCE, 4110 N FREEWAY BLVD, SACRAMENTO, CA, 95834
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
N/A
Principal Investigator
 NING HUANG
 (916) 921-6148
 NHUANG@VENTRIA.COM
Business Contact
 NING HUANG
Phone: (916) 921-6148
Email: NHUANG@VENTRIA.COM
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Inflammatory bowel disease (IBD), including Crohn's disease, is a chronic inflammation of the intestine, for which current therapies are inadequate. In industrialized countries, Crohn's disease affects about 1 in 500 individuals, and it is estimated that about one million Americans suffer from some form of IBD. Current hypotheses suggest that in the pathogenesis of all forms of IBD, intestinal microbes trigger inflammatory disease in genetically susceptible individuals. Over the past decade, epithelial cells of the intestine, and other tissues, have been identified as a source of defensins and other antimicrobial peptides. These molecules contribute to innate host defense of epithelial surfaces. One antimicrobial peptide expressed by epithelial cells of the human small intestine, human defensin-5 (HD5), is the prime focus of experiments in this grant proposal. Recent investigations provide strong evidence that deficient expression of HD5 is a predisposing factor for Crohn's disease of the ileum. Human defensins are currently not available commercially. Our aims seek to use a protein expression system, ExpressTec, which has been developed by Ventria Bioscience, to produce HD5 using cereal grains. Our proposed studies will yield a commercial source of HD5 that could be used to augment the deficient levels of this molecule in the intestine of ileal Crohn's disease patients. Thus, our efforts may result in a novel therapeutic strategy for the treatment of IBD,

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government